HF
NBIX icon

HRT Financial’s Neurocrine Biosciences NBIX Stock Holding History

HRT Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,404
Closed -$3.48M – 4958
2026
Q1 		$3.48M Buy
+26,404
New +$3.5M 0.01% 1227
2025
Q4 		– Sell
-6,862
Closed -$963K – 3730
2025
Q3 		$963K Buy
+6,862
New +$930K ﹤0.01% 1537
2025
Q2 		– Sell
-5,179
Closed -$572K – 3237
2025
Q1 		$572K Buy
+5,179
New +$656K ﹤0.01% 1391
2024
Q4 		– Sell
-44,395
Closed -$5.12M – 2955
2024
Q3 		$5.12M Buy
+44,395
New +$6.09M 0.03% 449
2024
Q2 		– Sell
-41,993
Closed -$5.79M – 2787
2024
Q1 		$5.79M Buy
41,993
+22,347
+114% +$3.05M 0.04% 229
2023
Q4 		$2.59M Sell
19,646
-57,117
-74% -$6.57M 0.02% 540
2023
Q3 		$8.63M Buy
+76,763
New +$8.08M 0.09% 161
2022
Q4 		– Sell
-19,599
Closed -$2.08M – 2899
2022
Q3 		$2.08M Sell
19,599
-24,311
-55% -$2.47M 0.02% 585
2022
Q2 		$4.28M Buy
43,910
+30,061
+217% +$2.77M 0.05% 300
2022
Q1 		$1.3M Sell
13,849
-9,196
-40% -$779K 0.01% 860
2021
Q4 		$1.96M Buy
23,045
+884
+4% +$81.3K 0.01% 667
2021
Q3 		$2.13M Buy
22,161
+14,306
+182% +$1.35M 0.01% 694
2021
Q2 		$764K Buy
+7,855
New +$753K 0.01% 1331
2021
Q1 		– Sell
-3,456
Closed -$331K – 2994
2020
Q4 		$331K Buy
+3,456
New +$334K 0.01% 1231
2019
Q4 		– Sell
-2,322
Closed -$209K – 1472
2019
Q3 		$209K Sell
2,322
-3,386
-59% -$316K 0.01% 1128
2019
Q2 		$481K Buy
+5,708
New +$469K 0.03% 421

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's NBIX Position: Q2 2026 in Review

HRT Financial sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 26,404 shares — an estimated $3.48M sold.

HRT Financial first reported a position in NBIX in Q2 2019 and held it in 16 quarters. The position peaked at $8.63M in Q3 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • HRT Financial reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 26,404 Neurocrine Biosciences shares in Q2 2026, an estimated $3.48M.
  • HRT Financial first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 16 quarters.
  • HRT Financial's Neurocrine Biosciences position peaked at $8.63M in Q3 2023.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.